Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer

Launched by FUDAN UNIVERSITY · Jul 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of targeted therapies used to treat breast cancer, specifically focusing on any blood-related side effects, known as hematological toxicities. Researchers want to understand how these side effects occur, what factors might influence them, and how they are managed in real-life settings. The study will look at information from 1,000 patients, both by reviewing past treatment records and collecting new data during their ongoing treatments.

To be eligible for this study, participants must have a confirmed diagnosis of breast cancer and either be currently receiving or have completed targeted therapy. They also need to have signed consent to participate. Pregnant or breastfeeding women, as well as those who cannot understand the study requirements, will not be included. Participants can expect to contribute their treatment experiences, which will help researchers learn more about managing these side effects effectively and improving care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • · The patients signed the informed consent and voluntarily participated in the study.
• • A definite diagnosis of any type of breast cancer.
• • Receiving or has completed targeted therapies.
• • Investigator judged that the patient need to receive or had received treatment or prevention for CTIT, CIN or CRA induced by targeted therapies.
• Exclusion Criteria:
• • · Pregnant or lactating women.
• • Failure to understand the study or to obtain informed consent.
• • The investigator determined other situations that are not suitable for inclusion.